SCHEMBL770448

SCHEMBL770448

CN1CCN(C(=O)CCC(=O)N2CCC3CCCC=C3C2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.44
HTT P42858 1/20 0.44
MCHR1 Q99705 2/20 0.40
KMT2A Q03164 1/20 0.39
GNAI3 P08754 3/20 0.36
GNAO1 P09471 3/20 0.36
GNAI1 P63096 3/20 0.36
KDM1A O60341 2/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
RAD52 P43351 1/20 0.36
MAOB P27338 1/20 0.36
NAMPT P43490 1/20 0.36
CHRM2 P08172 1/20 0.36
CHRM4 P08173 1/20 0.36
CHRM1 P11229 1/20 0.36
CHRM3 P20309 1/20 0.36
L3MBTL3 Q96JM7 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL771078 0.95 NPC1 (0.42) SMN1; SMN2HTTMCHR1KMT2AGNAI3
SCHEMBL770894 0.92 KDM1A (0.39) SMN1; SMN2HTTMCHR1KMT2AKDM1A
SCHEMBL771656 0.91 MAPK1 (0.36) SMN1; SMN2HTTMCHR1KMT2AALDH1A1
SCHEMBL770939 0.88 NPC1 (0.49) SMN1; SMN2KMT2AALDH1A1LMNACHRM2
SCHEMBL771900 0.88 ATM (0.39) SMN1; SMN2KMT2AALDH1A1L3MBTL1NPC1
SCHEMBL770696 0.85 MEN1 (0.38) SMN1; SMN2HTTKMT2AALDH1A1LMNA
SCHEMBL771570 0.85 L3MBTL3 (0.37) SMN1; SMN2HTTKMT2AALDH1A1LMNA
SCHEMBL769789 0.85 NPC1 (0.42) SMN1; SMN2HTTKMT2AGNAI3GNAO1
SCHEMBL770401 0.85 LMNA (0.39) SMN1; SMN2HTTKMT2AGNAI3GNAO1
SCHEMBL769773 0.84 HDAC3 (0.35) SMN1; SMN2HTTALDH1A1LMNANAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 SMN1; SMN2 3653/4885HTT 412/4885MCHR1 1409/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 SMN1; SMN2 3637/4885HTT 425/4885MCHR1 1438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.